Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma

Published:2011-04-19 Issue:10 Volume:104 Page:1544-1550
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Penel N,Glabbeke M V,Mathoulin-Pelissier S,Judson I,Sleijfer S,Bui B,Schoffski P,Ouali M,Marreaud S,Brouste V,Duhamel A,Hohenberger P,Blay J-Y

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2011136.pdf

Reference33 articles.

1. Ambalavanan N, Carlo WA, Shankara S, Bann CM, Emrich SL, Higgins RD, Tyson JE, O’Shea TM, Laptook AR, Ehrenkranz RA, Donovan EF, Walsh MC, Goldberg RN, Das A, National Institute of Child Health and Human Development Neonatal Research Network (2006) Predicting outcomes of neonates diagnosed with hypoxemic-ischemic encephalopathy. Pediatrics 118: 2084–2093

2. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL (1993) An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11: 1276–1285

3. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634–1639

4. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2009) Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27: 2692–2696

5. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S (2008) Clinical outcome and prognosis factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 98: 1029–1033

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Death Incidence and Prediction Among Patients With Hypopharynx Squamous Cell Carcinomas;Ear, Nose & Throat Journal;2023-08-13

2. Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma;International Journal of Radiation Oncology*Biology*Physics;2022-11

3. Surgical Principles of Primary Retroperitoneal Sarcoma in the Era of Personalized Treatment: A Review of the Frontline Extended Surgery;Cancers;2022-08-24

4. Treatment Strategy for Elderly Patients with Soft Tissue Sarcoma;Current Oncology Reports;2022-02-22

5. Early death in supraglottic laryngeal squamous cell carcinoma: A population-based study;Ear, Nose & Throat Journal;2022-02-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3